Other OTC • Healthcare • Biotechnology • US • USD
PhaseBio Pharmaceuticals, Inc. (PHASQ) has a consensus analyst rating of Hold, based on 5 analysts covering the stock. Of those, 2 recommend buying, 3 recommend holding, and 0 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
